Fundraising Fox
Biolinq
San Diego, US · 134 employees on LinkedIn · 14 known investors
Find your way into Biolinq
Biolinq develops the Shine sensor, a needle-free glucose monitor that measures glucose along with physical activity and sleep in a single wearable device. It uses an on-device LED light system to signal glucose levels in real time and pairs with a mobile app that provides personalized health insights and trend tracking.
Founders & leadership
Board
Investors · 14
How we know: Alpha Wave Global's portfolio page · the company's own site · Not right? Tell us
How we know: RiverVest Venture Partners's portfolio page · the company's own site · funding news · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: Averin Capital's portfolio page · Not right? Tell us
How we know: Beyond Capital's portfolio page · Not right? Tell us
How we know: BOLD Longevity's portfolio page · Not right? Tell us
How we know: Global Health Investment Corporation's portfolio page · Not right? Tell us
How we know: Hikma Ventures's portfolio page · board seat on SEC Form D · funding news · the VCSheet dataset · Not right? Tell us
How we know: LifeSci Venture Partners's portfolio page · funding news · Not right? Tell us
How we know: M Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Funding
SEC filings, press & company announcements$347.4M disclosed across 9 of 11 rounds · 2016–2025
- $100MSeries CApr 2025 · 3 sourcesSource ↗
▶$90MraisedMar 2025 · 45 investors · BiotechnologyRule 506(b)
- CHRIS DIMITROPOULOSDirector
- DAVID BERRYDirector
- DEREK RAPPDirector
- ZINA AFFAS BESSEDirector
- RICHARD YANGExecutive Officer, Director
- THAD JOHNSONDirector
- JARED TANGNEYExecutive Officer
- DAN BRADBURYDirector
- DAVID ARIDAExecutive Officer
- Offering amount
- $100M
- Amount sold
- $90M
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$59.1MraisedSep 2024 · 43 investors · BiotechnologyRule 506(b)
- DEREK RAPPDirector
- THAD JOHNSONDirector
- CHRIS DIMITROPOULOSDirector
- DAVID BERRYDirector
- JARED TANGNEYExecutive Officer
- DAN BRADBURYDirector
- RICHARD YANGExecutive Officer, Director
- DAVID ARIDAExecutive Officer
- ZINA AFFAS BESSEDirector
- Offering amount
- $59.1M
- Amount sold
- $59.1M
- Sales commissions
- $550K
- Placement agents
- J.P. Morgan Securities LLC
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$77.9MraisedJun 2022 · 62 investors · BiotechnologyRule 506(b)
- Jared TangneyExecutive Officer
- Dan BradburyDirector
- Thad JohnsonDirector
- Nancy HongDirector
- Richard YangExecutive Officer, Director
- Offering amount
- $105.6M
- Amount sold
- $77.9M
- Sales commissions
- $1.6M
- Proceeds to insiders
- $35K
- Placement agents
- Covington Associates, LLC
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.2MraisedMar 2021 · 21 investors · BiotechnologyRule 506(b)
- Daniel BradburyDirector
- Richard YangExecutive Officer, Director
- Edward KliphuisDirector
- Lana GhanemDirector
- Jared TangneyExecutive Officer, Director, Promoter
- Offering amount
- $6M
- Amount sold
- $5.2M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.6MraisedJul 2020 · 17 investors · BiotechnologyRule 506(b)
- Lana GhanemDirector
- Jared TangneyExecutive Officer, Director, Promoter
- Joshua WindmillerExecutive Officer, Director, Promoter
- Daniel BradburyDirector
- Edward KliphuisDirector
- Offering amount
- $10M
- Amount sold
- $3.6M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedMar 2019 · 9 investors · BiotechnologyRule 506(b)
- Edward KliphuisDirector
- Daniel BradburyDirector
- Lana GhanemDirector
- Joshua WindmillerExecutive Officer, Director, Promoter
- Jared TangneyExecutive Officer, Director, Promoter
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.1MraisedNov 2017 · 17 investors · BiotechnologyRule 506(b)
- Lana GhanemDirector
- Edward KliphuisDirector
- Joshua WindmillerExecutive Officer, Director, Promoter
- Jared TangneyExecutive Officer, Director, Promoter
- Offering amount
- $13.1M
- Amount sold
- $8.1M
- First sale
- Nov 2017
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$450KraisedSep 2016 · 5 investors · BiotechnologyRule 506(b)
- Jared TangneyExecutive Officer, Director, Promoter
- Joshua WindmillerExecutive Officer, Director, Promoter
- Offering amount
- $750K
- Amount sold
- $450K
- Minimum investment
- $50K
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
5 people who came through Biolinq went on to found or lead other companies.
Frequently asked questions
- What does Biolinq do?
- Biolinq develops the Shine sensor, a needle-free glucose monitor that measures glucose along with physical activity and sleep in a single wearable device. It uses an on-device LED light system to signal glucose levels in real time and pairs with a mobile app that provides personalized health insights and trend tracking.
- Who founded Biolinq?
- Biolinq was founded by Jared Tangney.
- Who are Biolinq's investors?
- Biolinq's investors include Alpha Wave Global, RiverVest Venture Partners, Able Partners, Aphelion Capital, Averin Capital, Beyond Capital, BioBrit, BOLD Longevity and 6 more.
- How much funding has Biolinq raised?
- Biolinq has disclosed $347.4M raised across 9 of its 11 known rounds.
- Where is Biolinq headquartered?
- Biolinq is headquartered in San Diego, US.